Patients completing FTY@ Research Evaluating Effects of Daily Oral Therapy in MS ( FREEDOMS ) were eligible for this dose-blinded , parallel-group extension study , continuing fingolimod @ mg/day or @ mg/day , or switching from placebo to either dose , randomized @:@ .